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Introduction
In the context of multiple HAART treatment modalities
it is critical that common understandings regarding the
motivators and barriers to treatment commencement
a n ds w i t c h i n ga r es h a r e db yboth prescribing clinicians
and PLHIV.
Materials and methods
We conducted an online survey of 254 people living
with HIV (PLHIV) in Australia and structured inter-
views with 18 clinicians (HIV S100 prescribers). PLHIV
had a median age of 47.5 years. Overall, 87.4% of
respondents were currently taking ARV; 5.5% had taken
ARV in the past but not currently, and 7.1% had never
taken ARV. Clinicians were a mix of high caseload
experienced practitioners and newer low caseload
clinicians.
Results
When we examined the motivations for and barriers to
treatment commencement, PLHIV identified concerns
about potential side effects and the psychological conse-
quences of acknowledging potential physical decline.
Clinicians were most likely to assess readiness in terms
of ability to maintain adherence. PLHIV relied on the
clinician initiating and advising treatment commence-
ment. Clinicians identified process of clinical assess-
ment, ARV education and adherence training as the
antecedents of treatment initiation.
Similarly with switching treatments, PLHIV identified
concerns about side effect profiles, clinical markers and
the potential limiting of treatment options. Clinicians
identified resistance patterns, regimen potency and
adherence concerns as primary motivators for treatment
change. PLHIV generally expected any discussion of
switching to be initiated by the clinician. Clinicians dis-
cussed the process in terms of resistance testing and
patient education around treatment options.
Both PLHIV and clinicians identified the relationship
between them as the critical component of the processes
of commencing and changing ARV treatment. Clinicians
were keen to involve PLHIV in the decision-making
process and PLHIV had a high degree of trust in their
clinicians’ knowledge and judgement.
Conclusions
Treatment discussions need to occur frequently. There
is evidence of resistance on the part of patients to
change unless they are experiencing significant side
effects. Clinicians may focus unduly on adherence while
PLHIV are more concerned about side effects and dis-
ease progression. The valued relationship between clini-
cian and PLHIV provides a fertile basis for improved
treatment discussion.
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